title: Micronized purified flavonoid fraction in pretreating CABG patients.
abstract: The aim of the present study was to determine whether oral pretreatment with micronized purified flavonoid fraction (Daflon) has beneficial effects on cardiac function and outcome after cardiac operations. This prospective, randomized trial enrolled 43 patients who had an impaired preoperative left ventricular ejection fraction of less than 0.50 (mean, 0.45 +/- 0.04) and a mean New York Heart Association functional class status of 2.30 +/- 0.74; all were scheduled for elective coronary artery bypass grafting. Patients who were randomized to the Daflon group (n=21) received oral Daflon 500 mg (6 tablets daily for 4 days, followed by 2 tablets for 3 days) preoperatively. Outcome variables included perioperative hemodynamic data, inotropic requirements, morbidity, and death, as well as cardiac ischemia and various outcome markers. Hemodynamic and biochemical data were collected before induction of anesthesia, perioperatively before starting cardiopulmonary bypass, immediately after bypass, and at the 24th postoperative hour. There was only 1 death (in the Daflon group). During the post-cardiopulmonary bypass period, troponin I and lactate dehydrogenase levels were significantly lower in the Daflon group. Also, the New York Heart Association status of the patients in the Daflon group was significantly lower postoperatively. Differences between the 2 groups in lengths of stay in the intensive care unit and hospital, inotropic requirements, and left ventricular ejection fraction levels did not reach statistical significance. Orally administered Daflon might provide better outcomes for patients who have impaired cardiac function before undergoing cardiac operations that require cardiopulmonary bypass.
authors.affiliation: Department of Cardiovascular Surgery, Ankara University School of Medicine, Dikimevi-Ankara 06340, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sirlak
authors.forename: A Ruchan
authors.initials: AR
authors.lastname: Akar
authors.forename: Sadik
authors.initials: S
authors.lastname: Eryilmaz
authors.forename: Elif Kuzgun
authors.initials: EK
authors.lastname: Cetinkanat
authors.forename: Evren
authors.initials: E
authors.lastname: Ozcinar
authors.forename: Bulent
authors.initials: B
authors.lastname: Kaya
authors.forename: Atilla Halil
authors.initials: AH
authors.lastname: Elhan
authors.forename: Umit
authors.initials: U
authors.lastname: Ozyurda
mesh_terms: D000284:Administration, Oral; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000401:mortality; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D004145:Diosmin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D011300:Preoperative Care; D011446:Prospective Studies; D013318:Stroke Volume; D013607:Tablets; D013997:Time Factors; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood; D014421:Turkey; D016277:Ventricular Function, Left
chemical_list: D015415:Biomarkers; D002316:Cardiotonic Agents; D013607:Tablets; D019210:Troponin I; D004145:Diosmin; D007770:L-Lactate Dehydrogenase
references.citation: Int J Microcirc Clin Exp. 1995;15 Suppl 1:17-21
references.pmid: 8748884
references.citation: Lab Invest. 1996 Jan;74(1):86-107
references.pmid: 8569201
references.citation: Atherosclerosis. 2007 Oct;194(2):397-402
references.pmid: 16962598
references.citation: Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2226-32
references.pmid: 11031208
references.citation: J Vasc Res. 1999;36 Suppl 1:3-10
references.pmid: 10474045
references.citation: J Vasc Res. 1999;36 Suppl 1:11-4
references.pmid: 10474046
references.citation: Mol Cell Biochem. 2003 May;247(1-2):23-30
references.pmid: 12841627
references.citation: World J Gastroenterol. 2008 Aug 14;14(30):4763-70
references.pmid: 18720536
references.citation: Int J Microcirc Clin Exp. 1994 Jan-Apr;14(1-2):50-5
references.pmid: 7960444
references.citation: J Lab Clin Med. 1999 Nov;134(5):536-45
references.pmid: 10560948
references.citation: J Vasc Res. 1999;36 Suppl 1:15-23
references.pmid: 10474047
references.citation: J Am Coll Cardiol. 2006 Sep 5;48(5):939-47
references.pmid: 16949483
references.citation: Eur J Vasc Endovasc Surg. 1999 Apr;17(4):313-8
references.pmid: 10204053
references.citation: Vasc Med. 1997;2(3):203-13
references.pmid: 9546969
references.citation: Arch Pharm Res. 2006 Jun;29(6):503-7
references.pmid: 16833019
references.citation: Angiology. 1997 May;48(5):391-9
references.pmid: 9158383
references.citation: Eur J Cardiothorac Surg. 1999 Jul;16(1):9-13
references.pmid: 10456395
references.citation: J Pathol. 1979 Nov;129(3):125-33
references.pmid: 529011
references.citation: J Am Coll Cardiol. 2006 Jul 4;48(1):1-11
references.pmid: 16814641
references.citation: Ann Thorac Surg. 2001 Jan;71(1):226-32
references.pmid: 11216752